I don't consider this a slow down. Just business a

I don't consider this a slow down. Just business as usual. I agree that we are all far too anxious. We're only at the end of cohort two and we've been updated on the status of DLT in both cohorts. I know we were all hoping for some p21 data and even without it I was expecting to hear about the blood test results from cohort 1 but it doesn't shock me that they haven't released it. The first cohort was a very low dose and the animal studies indicated to me anyway that we need to be pumping higher doses before we can really expect some interesting results. I'm starting to think that ASCO may be the platform for some good news in june. I also think this lull could last into early summer with modest SP movement but I look forward to big catalysts in Q3 & 4. Maybe some good buying opportunities ahead. Just my opinion and I am frequently wrong.